Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

被引：0
|
作者：
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Izquierdo, Antonia Rodriguez
Martin, Eva Maria Donato
Garcia-Sancho, Alejandro Martin
Sandoval-Sus, Jose David
Tilly, Herve
Vandenberghe, Elizabeth
Hirata, Jamie
Choudhry, Priya
Chang, Yi Meng
Musick, Lisa
McMillan, Andrew
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Grp Hosp Henri Mondor, Lymphoid Malignancies Unit, Creteil, France
[3] ICO HU Germans Trias I Pujol, Barcelona, Spain
[4] Univ Hosp Ulm, Ulm, Germany
[5] Hosp Univ 12 Octubre, Serv Hemat, Madrid, Spain
[6] Hosp Univ Dr Peset Serv Hematol, Salamanca, Spain
[7] Hosp Clin Univ Salamanca, Serv Hematol, Salamanca, Spain
[8] Mem Healthcare Inst, Moffitt Canc Ctr, Pembroke Pines, FL USA
[9] Ctr Henri Becquerel, Dept Hematol, Rouen, France
[10] Ctr Henri Becquerel, U1245, Rouen, France
[11] Univ Rouen, Rouen, France
[12] St James Hosp Canc Clin Trials Off, Dublin, Ireland
[13] Genentech Inc, South San Francisco, CA USA
[14] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[15] Nottingham Univ Hosp NHS Trust, Ctr Clin Haematol, Nottingham, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7551
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [32] Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Haioun, C.
    Morschhauser, F.
    Jourdan, E.
    Karsenti, J.
    Hess, G.
    Duehrsen, U.
    Kravchenko, S.
    van Hal, G.
    Hahka-Kemppinen, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study
    Budde, L. Elizabeth
    Olszewski, Adam J.
    Assouline, Sarit
    Lossos, Izidore S.
    Diefenbach, Catherine
    Kamdar, Manali
    Ghosh, Nilanjan
    Modi, Dipenkumar
    Sabry, Waleed
    Naik, Seema
    Mehta, Amitkumar
    Nakhoda, Shazia K.
    Smith, Stephen D.
    Dorritie, Kathleen
    Jia, Ting
    Pham, Song
    Huw, Ling-Yuh
    Wu, Hao
    To, Iris
    Wei, Michael C.
    Chavez, Julio C.
    BLOOD, 2023, 142
  • [34] Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Preliminary Phase Ib/II Data supports the controllable Safety and encouraging Efficacy in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL)
    Hutchings, M.
    Sureda, A.
    Terol, M. J.
    Bosch, F.
    Corradini, P.
    Stauffer, Larsen T.
    Rueda, Dominguez A.
    Panchal, A.
    Bottos, A.
    Carlile, D.
    Wang, Y.
    de L'Etang, Filezac A.
    Tandon, M.
    Sellam, G.
    Gritti, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 54 - 54
  • [35] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA OR DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS OF A PHASE 1B/2 STUDY
    Matasar, M.
    Herrera, A. F.
    Kamdar, M.
    Mehta, A.
    Assouline, S.
    Fleury, I.
    Kim, T. M.
    Kim, W. S.
    Bosch, F.
    Radford, J.
    Flowers, C. R.
    Bu, L.
    Hong, W. -J.
    Sehn, L. H.
    HAEMATOLOGICA, 2017, 102 : 173 - 173
  • [36] Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study
    Yasenchak, Christopher
    Kim, Jeong-A
    Hahn, Uwe
    Kim, Won-Seog
    Fleury, Isabelle
    Laribi, Kamel
    Bergua Burgues, Juan Miguel
    Bouabdallah, Krimo
    Forward, Nicholas
    Bijou, Fontanet
    MacDonald, David
    Portell, Craig
    Ghesquieres, Herve
    Nowakowski, Grzegorz
    Rustia, Evelyn
    Fanale, Michelle
    Jie, Fei
    Bartlett, Nancy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S490 - S491
  • [37] Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
    Gritti, Giuseppe
    Marlton, Paula
    Phillips, Tycel J.
    Arthur, Christopher
    Bannerji, Rajat
    Corradini, Paolo
    Johnston, Anna
    Seymour, John F.
    Yuen, Sam
    Hirata, Jamie
    Musick, Lisa
    Saha, Sourish
    Croft, Brandon
    Flowers, Christopher
    BLOOD, 2020, 136
  • [38] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [39] Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Hutchings, Martin
    Sureda, Anna
    Terol, Maria Jose
    Albareda, Francesc Bosch
    Corradini, Paolo
    Larsen, Thomas Stauffer
    Dominguez, Antonio Rueda
    Panchal, Anesh
    Bottos, Alessia
    Carlile, David
    Wang, Yanjie
    De L'Etang, Audrey Filezac
    Tandon, Maneesh
    Sellam, Gila
    Gritti, Giuseppe
    BLOOD, 2021, 138
  • [40] Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis☆
    Farooqi, Hanzala Ahmed
    Ullah, Muhammad Saffi
    Raza, Ahmed
    Sadiq, Zain
    Shaikh, Wardah Ali
    Muhammad, Rahmah
    Hussain, Muhammad Shoaib
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 207
12345